Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
Beyond its established utility in antibacterial research, Ethyl 7-bromo-1-cyclopropyl-8-(difluoromethoxy)-4-oxo-1,4-dihydroquinoline-3-carboxylate (CAS 194805-07-7) is emerging as a compound of significant interest in the field of anticancer drug discovery. The quinoline scaffold itself is found in various biologically active molecules, and strategic modifications can imbue it with potent cytotoxic properties against cancer cells. This specific intermediate, with its unique difluoromethoxy and bromo functionalities, presents a promising foundation for novel oncology therapeutics.
Research into quinoline derivatives has shown their ability to interfere with crucial cellular processes involved in cancer proliferation, such as DNA replication and repair, and programmed cell death (apoptosis). The difluoromethoxy group can enhance the lipophilicity and cellular uptake of candidate drugs, while the bromine atom offers a reactive site for further structural diversification, allowing chemists to optimize drug efficacy and specificity. When scientists search for 'advanced pharmaceutical intermediates' or 'anticancer research chemicals', compounds like this become critical components in their experimental designs.
For academic institutions and pharmaceutical companies engaged in anticancer R&D, sourcing high-quality Ethyl 7-bromo-1-cyclopropyl-8-(difluoromethoxy)-4-oxo-1,4-dihydroquinoline-3-carboxylate is essential. Working with reputable 'pharmaceutical intermediate manufacturers' ensures that the material's purity and structural integrity meet the rigorous demands of preclinical studies. This allows researchers to confidently investigate its potential as a precursor to new chemotherapeutic agents, targeting various cancer types.
The exploration of this quinoline derivative in oncology is a testament to the continuous innovation within medicinal chemistry. As research progresses, understanding its potential synergistic effects with other treatments or its specific mechanisms of action against different cancer cell lines will be key. Access to reliable suppliers of such advanced intermediates is fundamental to unlocking these new therapeutic possibilities and driving forward the fight against cancer.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
